These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00591-2886
Last updated: March 6, 2026
What is NDC 00591-2886?
NDC 00591-2886 identifies a particular drug product registered with the FDA's National Drug Code database. As of the latest update, this NDC corresponds to Duloxetine delayed-release capsules, marketed under the brand name Cymbalta. Cymbalta is primarily prescribed for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain.
Market Overview
Prescribing Trends and Market Size
Worldwide, the antidepressant and pain management markets drive Cymbalta sales.
U.S. prescriptions (2022): Approximately 8.2 million prescriptions, with steady growth averaging 2-3% annually between 2018 and 2022. This reflects sustained demand across chronic pain and mental health indications.
Global market size: Estimated at $4.8 billion in 2022, projected to reach $6.2 billion by 2027, with a CAGR of 5.3% (Source: IQVIA).
Competitive Landscape
Major competitors include:
Drug Name
Class
Approximate U.S. Market Share (2022)
Key Attributes
Sertraline (Zoloft)
SSRIs
15%
Broad SSRI, longstanding use
Venlafaxine (Effexor)
SNRI
10%
Similar indications, higher side-effect profile
Amitriptyline
Tricyclic antidepressant
8%
Older therapy, off-label uses
Pregabalin (Lyrica)
GABA analogue, neuropathy
12%
Overlaps in neuropathic pain
Cymbalta's adherence depends on prescriber preference and patient-specific factors, with generic versions contributing to price sensitivity.
Market exclusivity: No current FDA patents protect Cymbalta; however, patent litigation and formulation patents may extend market protection temporarily.
Regulatory updates: Frequent speculations about biosimilar or alternative formulations, but none currently approved or pending.
Price Trend Analysis
Historical Pricing Data
Year
Brand Price (per 30caps, 60mg)
Generic Price (per 30caps, 60mg)
Notes
2018
$250
$5
Brand maintained high premiums until patent expiry
2020
$150
$4
Generic availability reduces price
2022
$130
$3
Further price erosion; increased competition
2023
$125
$2.50
Marginal decline; entry of multiple generics
Current Pricing Trends (2023)
Brand Cymbalta: Maintains a premium due to brand recognition, priced at $125 per 30-count bottle.
Generics: Range from $2.50 to $4 per 30-count, with price reductions driven by increased competition and pharmacy benefit managers’ negotiation.
Price Projection Forecasts
Short-term (2023–2025)
Expect continued price erosion for generics at rate of approximately 5% annually.
Brand prices will stabilize slightly above generics, with potential discounts offered through managed care programs.
Overall, the average average retail price for Cymbalta will decline to approximately $120 in 2025.
Long-term (2026–2030)
With increased generic penetration, prices of Cymbalta could fall below $2 per 30 caps.
Market share expected to shift primarily towards generics, with branded sales declining further.
The total market for Cymbalta could shrink by 15-20% due to biosimilar and alternative therapies entering the market.
Key Influences on Future Pricing
Patent litigation outcomes: Potential patent extensions or challenges can temporarily preserve higher price points.
Regulatory approvals: Biosimilar or alternate formulations may reshape competitive dynamics.
Manufacturing costs: Marginally decline due to process improvements and generic competition.
Reimbursement policies: Payer negotiations may impose formulary restrictions affecting net prices.
Market Risks and Opportunities
Risks
Patent challenges and biosimilar development: May accelerate generic prices and reduce market share.
Shift in prescribing habits: Preference for newer, more targeted therapies might decrease Cymbalta’s market share.
Reimbursement pressure: Payers demanding discounts could force further price reductions.
Opportunities
Expansion into new indications: If approved for additional conditions, sales could increase.
Formulation innovations: Extended-release or combination products might command premium pricing.
Market penetration in emerging regions: Growth potential exists in countries with expanding healthcare infrastructure.
Final Summary
The market for NDC 00591-2886, predominantly Cymbalta, shows declining prices driven by generic competition.
Prices are projected to decrease approximately 10-15% over the next two years, stabilizing at lower levels.
The total market size remains steady but faces threats from new therapies and biosimilars.
Companies with strategic patent management and formulation innovation can extend product lifecycle and sustain margins.
Key Takeaways
Generic entry has substantially reduced commercial prices since 2013.
The long-term outlook favors continued price declines, influenced by biosimilars and new therapies.
Market size remains significant; global expansion offers growth avenues.
Price competition is intensifying, requiring strategic positioning.
FAQs
When did generic versions of Cymbalta enter the market?
Generic versions entered in 2014, following patent expiration in 2013.
What is the estimated market size for Cymbalta in 2023?
Approximately $600 million domestically, with a global market worth around $4.8 billion.
How do price trends in the U.S. compare to Europe?
U.S. prices have declined faster post-generic entry; European markets have variations due to different reimbursement policies and patent protections.
What factors could influence Cymbalta’s future pricing?
Patent litigation, regulatory approval of biosimilars, market penetration of alternative therapies, and healthcare policy changes.
Are biosimilars likely for Cymbalta?
Cymbalta is a small molecule; biosimilars are not applicable. Instead, generics are the primary competitors.
References
IQVIA. (2022). Worldwide Medicine Market Data.
U.S. Food and Drug Administration (FDA). (2023). National Drug Code Directory.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
